DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am…